Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MALT1 | Q9UDY8 | 12/20 | 0.76 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.67 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.67 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.67 |
| ▸ | KCNH2 | Q12809 | 1/20 | 0.67 |
| ▸ | PIM1 | P11309 | 7/20 | 0.61 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.51 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.51 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.51 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3719743 | 0.93 | MALT1 (0.67) | MALT1CYP3A4CYP2C9CYP2C19KCNH2 | |
| SCHEMBL3719746 | 0.93 | MALT1 (0.67) | MALT1CYP3A4CYP2C9CYP2C19KCNH2 | |
| SCHEMBL2763440 | 0.92 | MALT1 (0.67) | MALT1CYP3A4CYP2C9CYP2C19KCNH2 | |
| SCHEMBL612448 | 0.90 | MALT1 (0.64) | MALT1CYP3A4CYP2C9CYP2C19KCNH2 | |
| SCHEMBL24441137 | 0.82 | MALT1 (1.00) | MALT1CYP3A4CYP2C9CYP2C19KCNH2 | |
| SCHEMBL24441136 | 0.82 | MALT1 (1.00) | MALT1CYP3A4CYP2C9CYP2C19KCNH2 | |
| SCHEMBL14422647 | 0.76 | PIM1 (1.00) | PIM1 | |
| SCHEMBL14422668 | 0.74 | PIM1 (1.00) | MALT1PIM1ALDH1A1 | |
| SCHEMBL14422795 | 0.74 | PIM1 (0.64) | MALT1CYP3A4CYP2C9CYP2C19KCNH2 | |
| SCHEMBL14422761 | 0.72 | PIM1 (0.65) | MALT1CYP3A4CYP2C9CYP2C19KCNH2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20120165326-A1 | DERIVATIVES OF 6-(6-SUBSTITUTED-TRIAZOLOPYRIDAZINE-SULFANYL) 5-FLUORO BENZOTHIAZOLES AND 5-FLUORO BENZIMIDAZOLES, PREPARATION THEREOF, USE THEREOF AS DRUGS, AND USE THEREOF AS MET INHIBITORS | SANOFI (FR) | 2012-06-28 | — | — | US | disclosed |
| EP-2393793-A1 | DERIVATIVES OF 6-(6-SUBSTITUTED-TRIAZOLOPYRIDAZINE-SULFANYL) 5-FLUORO-BENZOTHIAZOLES AND 5-FLUORO-BENZIMIDAZOLES, PREPARATION THEREOF, USE THEREOF AS DRUGS, AND USE THEREOF AS MET INHIBITORS | SANOFI (FR) | 2011-12-14 | — | — | EP | disclosed |
| EP-2393790-A1 | DERIVATIVES OF 6-(6-O-CYCLOALKYL OR 6-NH-CYCLOALKYL-TRIAZOLOPYRIDAZINE-SULFANYL) BENZOTHIAZOLES AND BENZIMIDAZOLES, PREPARATION THEREOF, USE THEREOF AS DRUGS, AND USE THEREOF AS MET INHIBITORS | SANOFI (FR) | 2011-12-14 | — | — | EP | disclosed |
| WO-2010089506-A1 | DERIVATIVES OF 6-(6-O-CYCLOALKYL OR 6-NH-CYCLOALKYL-TRIAZOLOPYRIDAZINE-SULFANYL) BENZOTHIAZOLES AND BENZIMIDAZOLES, PREPARATION THEREOF, USE THEREOF AS DRUGS, AND USE THEREOF AS MET INHIBITORS | SANOFI-AVENTIS (FR) | 2010-08-12 | — | — | WO | disclosed |
| WO-2010089509-A1 | DERIVATIVES OF 6-(6-SUBSTITUTED-TRIAZOLOPYRIDAZINE-SULFANYL) 5-FLUORO-BENZOTHIAZOLES AND 5-FLUORO-BENZIMIDAZOLES, PREPARATION THEREOF, USE THEREOF AS DRUGS, AND USE THEREOF AS MET INHIBITORS | SANOFI-AVENTIS (FR) | 2010-08-12 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120165326-A1 | DERIVATIVES OF 6-(6-SUBSTITUTED-TRIAZOLOPYRIDAZINE-SULFANYL) 5-FLUORO BENZOTHIAZOLES AND 5-FLUORO BENZIMIDAZOLES, PREPARATION THEREOF, USE THEREOF AS DRUGS, AND USE THEREOF AS MET INHIBITORS | MET, NR4A1, NR1I3 | MALT1 1245/4885CYP3A4 42/4885CYP2C9 204/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.